Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CARFILZOMIB Cause Brain natriuretic peptide increased? 51 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 51 reports of Brain natriuretic peptide increased have been filed in association with CARFILZOMIB (KYPROLIS). This represents 0.2% of all adverse event reports for CARFILZOMIB.

51
Reports of Brain natriuretic peptide increased with CARFILZOMIB
0.2%
of all CARFILZOMIB reports
4
Deaths
18
Hospitalizations

How Dangerous Is Brain natriuretic peptide increased From CARFILZOMIB?

Of the 51 reports, 4 (7.8%) resulted in death, 18 (35.3%) required hospitalization, and 1 (2.0%) were considered life-threatening.

Is Brain natriuretic peptide increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CARFILZOMIB. However, 51 reports have been filed with the FAERS database.

What Other Side Effects Does CARFILZOMIB Cause?

Plasma cell myeloma (2,238) Off label use (2,120) Death (1,442) Thrombocytopenia (1,265) Fatigue (1,048) Pneumonia (1,016) Pyrexia (969) Anaemia (910) Dyspnoea (881) Neutropenia (874)

What Other Drugs Cause Brain natriuretic peptide increased?

SACUBITRIL\VALSARTAN (252) MACITENTAN (192) TADALAFIL (176) ASPIRIN (157) SELEXIPAG (156) RIVAROXABAN (134) ROSUVASTATIN (133) TAMSULOSIN (131) CLOPIDOGREL BISULFATE (127) TREPROSTINIL (124)

Which CARFILZOMIB Alternatives Have Lower Brain natriuretic peptide increased Risk?

CARFILZOMIB vs CARGLUMIC ACID CARFILZOMIB vs CARIPRAZINE CARFILZOMIB vs CARISOPRODOL CARFILZOMIB vs CARMUSTINE CARFILZOMIB vs CARTEOLOL

Related Pages

CARFILZOMIB Full Profile All Brain natriuretic peptide increased Reports All Drugs Causing Brain natriuretic peptide increased CARFILZOMIB Demographics